Roy D. Baynes net worth and biography

Roy Baynes Biography and Net Worth

Director of Natera
Roy Baynes has served as a member of our board of directors since July 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.

What is Roy D. Baynes' net worth?

The estimated net worth of Roy D. Baynes is at least $58,656.00 as of August 7th, 2020. Dr. Baynes owns 1,300 shares of Natera stock worth more than $58,656 as of February 7th. This net worth approximation does not reflect any other investments that Dr. Baynes may own. Learn More about Roy D. Baynes' net worth.

How do I contact Roy D. Baynes?

The corporate mailing address for Dr. Baynes and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Roy D. Baynes' contact information.

Has Roy D. Baynes been buying or selling shares of Natera?

Roy D. Baynes has not been actively trading shares of Natera over the course of the past ninety days. Most recently, Roy D. Baynes sold 1,300 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $53.47, for a transaction totalling $69,511.00. Following the completion of the sale, the director now directly owns 1,300 shares of the company's stock, valued at $69,511. Learn More on Roy D. Baynes' trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 62 times. They sold a total of 164,110 shares worth more than $6,807,068.72. The most recent insider tranaction occured on February, 1st when CFO Michael Burkes Brophy sold 19,326 shares worth more than $844,159.68. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 2/1/2023.

Roy D. Baynes Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2020Sell1,300$53.47$69,511.001,300View SEC Filing Icon  
See Full Table

Roy D. Baynes Buying and Selling Activity at Natera

This chart shows Roy D Baynes's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $45.12
Low: $42.84
High: $45.15

50 Day Range

MA: $40.83
Low: $36.57
High: $46.55

2 Week Range

Now: $45.12
Low: $26.10
High: $74.82


691,355 shs

Average Volume

1,335,102 shs

Market Capitalization

$4.40 billion

P/E Ratio


Dividend Yield



A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]